GT Medical Technologies has announced that the first patients have been enrolled in the randomised BRIDGES trial evaluating whether implanting GammaTile—a US Food and Drug Administration (FDA)-cleared, bioabsorbable collagen device embedded with radiation seeds—at the time of surgery can improve survival outcomes for people with newly diagnosed glioblastoma (GBM).
The first patient enrolment in the US BRIDGES trial was achieved at Westchester Medical Center in Valhalla, USA by neurosurgeon Simon Hanft.
“All of us at Westchester Medical Center are excited about giving our patients access to the BRIDGES trial and what it could mean for our patients suffering from GBM,” Hanft stated. “We have utilised GammaTile successfully for a number of years, and we look forward to a significant contribution to the BRIDGES trial in an effort to lead the exploration of new advancements in care for patients with GBM.”
“Although glioblastoma remains a challenging disease, meaningful progress is underway,” added Clark Chen (Brown University Health, Providence, USA. “The BRIDGES trial exemplifies this momentum, offering patients access to the most advanced therapies available in modern neuro-oncology. At Brown Health, we are proud to make this trial available to our patients.”
The GammaTile implant has been designed for patients with operable brain tumours. By delivering radiation directly from within—having been placed into the surgical cavity at the time of tumour removal—it provides immediate, localised treatment. This approach targets remaining cancer cells when they are at their lowest levels to help prevent regrowth while minimising radiation exposure to healthy brain tissue, according to GT Medical Technologies.
Since its full market launch in the USA in March 2020, GammaTile has been adopted by more than 100 leading centres.
“GT Medical Technologies is proud to announce that the first patients have been enrolled in the BRIDGES trial, a groundbreaking study that will examine the ability of GammaTile to increase survivability for patients with newly diagnosed GBM,” said Per Langoe, the company’s chief executive officer (CEO). “Patients who are newly diagnosed with GBM face an unacceptably poor prognosis, demonstrating a significant need for disruptive therapies that can improve the standard of care. With the recent completion of our ROADS trial for newly diagnosed brain metastases, we are very encouraged going into the BRIDGES trial.”
“GammaTile therapy is designed to be implanted at the time of GBM tumour resection, enabling radiation treatment to begin immediately rather than weeks after surgery,” added Michael Garcia, chief medical officer at GT Medical Technologies. “This represents a fundamental shift from the traditional care paradigm, where time between surgery and radiation allows for the tumour to start growing back. By delivering radiation from day one—when tumour burden is at its lowest—GammaTile offers a new way to rethink postoperative radiation. This approach underpins the promise of the BRIDGES trial and its potential to transform how GBM is treated.”
